BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
PR Newswire•29/10/2026•08:45 ET
2
Key Highlights
- ➤BioMarin (BMRN) licenses worldwide HM15421/GC1134A rights, excluding Korea
- ➤BioMarin will pay $70 million upfront for the Fabry disease therapy
- ➤GC and Hanmi could receive up to $405 million in development and commercial milestones
- ➤HM15421/GC1134A is a Phase 1/2, long-acting subcutaneous enzyme replacement therapy
- ➤BioMarin assumes subsequent development, manufacturing and commercialization outside Korea
Expert Statements
Alexander Hardy, President and Chief Executive Officer of BioMarin
“This agreement reflects our growing commitment to the Fabry community, building on the acquisition of Amicus earlier this year.”
Alexander Hardy, President and Chief Executive Officer of BioMarin
“HM15421/GC1134A has the potential to offer a new way of treating Fabry disease, and we believe it could be an important option for patients.”
Alexander Hardy, President and Chief Executive Officer of BioMarin
“As we continue to add to our clinical portfolio, both through internal research and external programs, HM15421/GC1134A is an excellent fit and could allow us to reach a new generation of patients with Fabry beyond those with mutations amenable to treatment with GALAFOLD.”
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease PR Newswire
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease
Get started
Create a free account to read the full story.